Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H4L7
UPID:
SMRCD_HUMAN
Alternative names:
ATP-dependent helicase 1
Alternative UPACC:
Q9H4L7; B7Z799; Q05D56; Q96SX1; Q9H017; Q9H860; Q9NPU9; Q9ULU7
Background:
The SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1, also known as ATP-dependent helicase 1, plays a pivotal role in DNA repair and heterochromatin organization. It exhibits intrinsic ATP-dependent nucleosome-remodeling activity, essential for DNA end resection of double-strand breaks and the maintenance of heterochromatin integrity.
Therapeutic significance:
Linked to diseases such as Adermatoglyphia, Basan syndrome, and Huriez syndrome, this protein's understanding could pave the way for innovative treatments targeting skin abnormalities and aggressive cancers.